TLDR
- ANKTIVA plus BCG saves over $100K per cystectomy compared to TAR-200 in Year 1.
- Complete responder costs drop by $313K in Year 1 with ANKTIVA plus BCG.
- ANKTIVA achieves a 49.6% response rate, outperforming TAR-200 at 45.9%.
- Medicare patients could benefit from lower treatment costs and durable results.
- Health economic analysis shows ANKTIVA plus BCG reduces overall system expenses.
ImmunityBio (IBRX) trades at $7.18, down 7.30% after releasing a major cost analysis of ANKTIVA plus BCG. The study highlights significant economic advantages compared to TAR-200 for treating BCG-unresponsive non-muscle-invasive bladder cancer. The findings provide new context for treatment selection in U.S. Medicare patients and underline potential healthcare savings.
ANKTIVA Plus BCG Demonstrates Cost Efficiency
The analysis compared ANKTIVA plus BCG with TAR-200 using data from QUILT-3.032 and SunRISe-1 trials. Researchers employed a multi-state Markov model to evaluate clinical outcomes and costs. The model included treatment acquisition, administration, healthcare use, radical cystectomy, and mortality.
Cost per cystectomy avoided showed ANKTIVA plus BCG saved $109,622 at Year 1 and $151,438 at Year 2. By Year 3, the savings reached $60,393 compared to TAR-200. These reductions were driven by lower drug costs and higher complete response rates.
Cost per cystectomy-free month also showed savings, starting at $9,370 in Year 1 and decreasing to $1,520 by Year 3. Cost per complete responder demonstrated reductions of $313,775 at Year 1 and $282,013 at Year 2. The consistent savings across multiple metrics emphasize the economic value of ANKTIVA plus BCG.
Clinical and Economic Implications
The analysis applied a matched-adjusted indirect comparison to evaluate response durability and clinical outcomes. ANKTIVA plus BCG achieved a 49.6% complete response rate versus 45.9% for TAR-200. These results suggest more effective treatment while reducing overall expenditures.
Medicare patients could benefit from broader access to ANKTIVA plus BCG due to its cost advantages. The economic model supports decision-making in healthcare systems by balancing clinical efficacy with affordability. Lower administration and drug acquisition costs contribute significantly to system-wide savings.
Durable responses and measurable cost reductions provide a clear advantage over alternative therapies. The findings reinforce the importance of integrating economic assessments into treatment planning. Hospitals and clinics may adjust protocols to incorporate therapies that offer both clinical and financial benefits.
Market and Industry Context
ImmunityBio’s research contributes to ongoing discussions on value-based oncology treatments. Health economic analyses have become essential tools for payers and providers. They help determine which therapies deliver optimal outcomes while controlling expenses.
The study was presented at the International Society for Pharmacoeconomics and Outcomes Research (ISPOR) 2026 conference. Researchers emphasized the intersection of innovation, patient outcomes, and cost-effectiveness in modern immunotherapy. ANKTIVA plus BCG may influence treatment guidelines for NMIBC CIS and similar indications.
ANKTIVA plus BCG presents measurable clinical benefits with direct economic savings. The treatment may reduce healthcare spending while improving patient outcomes. ImmunityBio strengthens its position as a commercial-stage immunotherapy leader by demonstrating cost-efficient innovation.
Get 3 Free Stock Ebooks
Discover top-performing stocks in AI, Crypto, and Technology with expert analysis.
- Top 10 AI Stocks - Leading AI companies
- Top 10 Crypto Stocks - Blockchain leaders
- Top 10 Tech Stocks - Tech giants
